🕒 Last update: loading…

Stock Kodiak Sciences Inc. KOD

Kodiak Sciences Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 913.38%

Price change 2019 → 2020: 104.17%

Price change 2020 → 2021: -42.27%

Price change 2021 → 2022: -57.78%

Price change 2022 → 2023: -57.54%

Price change 2023 → 2024: 227.30%

Price change 2024 → 2025: 181.01%

Price change 2025 → 2026: 252.15%

Price change 2026 (year to date): 278.40%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 1.01

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -22.65

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.00% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Kodiak Sciences Inc.–1.01–🔒
Ionis Pharmaceuticals, Inc.–5.34+15.5 %–
Hims & Hers Health, Inc.–2.07+74.7 %–
Doximity, Inc.21.20.01+33.4 %–
Merit Medical Systems, Inc.22.30.57+11.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Kodiak Sciences Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
5.38
safe zone (above 2.99)
Piotroski Score
0 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.18 x
low debt
Fiscal year20212022202320242025
Cash and investments732 m479 m286 m168 m210 m
Total Debt180 m188 m182 m70.3 m159 m
Net Debt-552 m-2.7 m-104 m-97.7 m-50.7 m
Equity663 m436 m266 m150 m157 m
Total assets904 m667 m479 m336 m352 m
Operating cash flow-182 m-206 m-154 m-117 m-136 m
Investments (capex)63.3 m47.4 m41.4 m400,000506,000
Free cash-flow-246 m-254 m-196 m-118 m-137 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-26.53 x
Price / book value538.04 x
Return on Equity (ROE)-66.1 %
Return on Invested Capital (ROIC)-161.3 %
Net margin0.0 %
Debt / equity3.70 x
Current ratio1.62 x
Free cash-flow yield-2.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Kodiak Sciences Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
19 analysts
Average price target
98.83 USD
from n/a to n/a, 12 targets over 12 months
Gap with the share price
-0.5 %
price 99.30 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 14hold 4sell 1strong sell 0

Average target over the last 3 months: 98.83 USD (6 targets).

Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Kodiak Sciences Inc.

Large funds tracked
22
hold the stock as of 2026Q2
Executives (insiders)
86 / 8
86 purchases, 8 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street4.8 m189 m0.0 %+115.0 %2026Q2
BlackRock4.1 m161 m0.0 %+5.1 %2026Q2
T. Rowe Price3.2 m127 m0.0 %+59.3 %2026Q2
Goldman Sachs2.3 m90.2 m0.0 %+37.1 %2026Q2
Vanguard Group2.3 m64.7 m0.0 %+18.6 %2025Q4
Geode Capital Management1.1 m41.4 m0.0 %+6.3 %2026Q2
Wellington Management793,61330.9 m0.0 %+81.9 %2026Q2
Adage Capital Partners500,00019.5 m0.0 %-13.0 %2026Q2

Latest insider transactions

DatePersonSideAmount
05/11/2026Baker Bros. Advisors Lppurchase463,293 USD
05/11/2026Baker Bros. Advisors Lppurchase8.1 m USD
04/11/2026Baker Bros. Advisors Lppurchase861,174 USD
04/11/2026Baker Bros. Advisors Lppurchase15.0 m USD
21/10/2026Borgeson John A.sale746,422 USD
21/10/2026Borgeson John A.sale149,588 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 04/10/2018
ISIN code
US50015M1099
Workforce
109
full-time employees
Chief executive
Victor Perlroth

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Kodiak Sciences Inc.

What is the Kodiak Sciences Inc. share price?

Latest recorded price: 111.19 USD on 13/11/2026, for a market cap of 7.0 bn USD.

What do analysts say about Kodiak Sciences Inc.?

Out of 19 analysts: 14 buy or strong buy, 4 hold, 1 sell or strong sell. Average price target: 98.83 USD, i.e. -0.5 % from the share price.

Is Kodiak Sciences Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US50015M1099).

How many employees does Kodiak Sciences Inc. have?

109 full-time employees according to the latest published profile.

Who runs Kodiak Sciences Inc.?

Victor Perlroth is the company's chief executive.

Which large funds own Kodiak Sciences Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, T. Rowe Price, Goldman Sachs, Vanguard Group.

07

Similar stocks